<DOC>
	<DOCNO>NCT00554216</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety two dose VI-0521 compare placebo treatment obesity adult population BMI ≥ 35 .</brief_summary>
	<brief_title>Study VI-0521 Compared Placebo Treatment Obesity Adults</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Body mass index ( BMI ) ≥ 35 kg/m2 Informed consent 70 year age less Triglyceride level ≤ 200 mg/dL treatment 0 1 medication Blood pressure ≤ 140/90 mmHg treatment 02 medication hypertension Fasting blood glucose level ≤ 110 mg/dL Stroke/myocardial infarction ( MI ) /unstable cardiovascular disease within 6 month Clinically significant renal , hepatic psychiatric disease Unstable thyroid disease replacement therapy Nephrolithiasis Obesity know genetic endocrine origin Participation formal weight loss program lifestyle intervention History glaucoma intraocular pressure Pregnancy breastfeed Alcohol abuse Smoking cessation within previous 3 month plan quit smoke study Eating disorder Cholelithiasis within past 6 month Excluded medication Type 2 diabetes Previous bariatric surgery History bipolar disorder psychosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Obesity , morbid obesity</keyword>
</DOC>